CLINICAL TRIAL article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1596270
Effectiveness and Safety Profile of Chidamide as Maintenance Therapy for Peripheral T-Cell Lymphoma: A Multicenter Real-World Study
Provisionally accepted
- 1Qingdao University, Qingdao, China
- 2Qingdao Central Hospital, Qingdao, Shandong Province, China
- 3The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
- 4Linyi People's Hospital, Linyi, Shandong Province, China
- 5Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Peripheral T-cell lymphoma (PTCL) is characterized by its significant variability and complexity as malignancy. Treatment outcome is poor with conventional chemotherapy. We sought to exploring the effectiveness and safety profile of chidamide monotherapy as maintenance regimen after chemotherapy.Methods: 69 patients for PTCL were included in the study and chidamide was administered as maintenance therapy at a dosage of 15-30 mg twice weekly (biw). The Kaplan-Meier survival analysis was employed to evaluate overall survival (OS) and progression-free survival (PFS).The average age of participants was 61 years (17-93). The most prevalent pathologic subtype identified was angioimmunoblastic T-cell lymphoma (AITL, 55.1%), and 43.5% (30/69) of patients were classified as intermediate or high-risk cases. Of the patients, 56.5% (n=39) underwent chidamide maintenance therapy after attaining complete response (CR). Over a median follow-up duration of 43.4 months (21.7-98.4), 47.8% of patients attained CR. The median overall survival (mOS) was not achieved, while the median progression-free survival (mPFS) stood at 54.8 months (95%CI, 21.68-72.78). 20% (6/30) of PR patients exhibited CR after chidamide. Individuals who attained CR at baseline demonstrated superior PFS compared to those in PR group. Baseline effectiveness was recognized as an independent prognostic indicator for PFS. Neutropenia was the most common hematologic TRAE, with a 20.3% rate of grade 3/4 events. Dosage modifications were required for 17 patients owing to adverse events, with no fatalities attributed to the treatment reported.In patients with PTCL, chidamide as a single-agent maintenance treatment demonstrates effectiveness and favorable tolerability, while the remission status prior to initiating maintenance therapy is a key factor influencing treatment outcomes. Notably, the depth of response after induction therapy alone cannot determine the long-term efficacy in PTCL. Maintenance therapy can not only bring more significant benefits to CR patients but also improve the prognosis of PR patients and reduce the risk of recurrence and progression, highlighting the core value of the "induction-maintenance" sequential model. Nevertheless, this study is exploratory, and further verification through prospective studies is still required.
Keywords: Peripheral T-cell Lymphoma1, Chidamide2, Maintenance therapy3, effectiveness4, safety5
Received: 19 Mar 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 Jiang, Zhang, Song, Xu, Wei, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ling Wang, Qingdao Central Hospital, Qingdao, 266000, Shandong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.